Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|May 18, 2004
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240Marc Pfister, Nancy E Martin, Lloyd P Haskell, et al.
Clinical Cardiology|October 17, 2022
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PADMarc P Bonaca, Michael Szarek, E Sebastian Debus, et al.
Lancet (London, England)|November 10, 2022
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P Schlaich, Marc Bellet, Michael A Weber, et al.
Circulation|October 18, 2023
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PADJennifer Rymer, Sonia S Anand, E Sebastian Debus, et al.
Journal of the American Heart Association|October 23, 2025
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PADShea Hogan, Michael Szarek, E Sebastian Debus, et al.
Journal of the American Heart Association|June 14, 2022
Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PADConnie N Hess, Iris Baumgartner, Sonia S Anand, et al.
Journal of the American College of Cardiology|August 21, 2024
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity RevascularizationMario Enrico Canonico, Cecilia C Low Wang, Judith Hsia, et al.
Vascular Medicine (London, England)|April 25, 2022
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PADShea E Hogan, Mark R Nehler, Sonia Anand, et al.
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
European Journal of Preventive Cardiology|August 31, 2021
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trialsSonia S Anand, Will Hiatt, Leanne Dyal, et al.
Pageof 2